Skip to main content

Overview

Pathogenesis of Tuberculosis

Approximately eight million people develop active tuberculosis (TB) each year with two million dying from the disease. In addition, it is estimated that one third of the world’s population is chronically infected with Mycobacterium tuberculosis (Mtb). Most individuals respond to infection with Mtb by mounting a strong cellular immune response that prevents active disease but does not sterilize the infection. Mtb has developed strategies to persist within macrophages, its major host cells, even in the face of fully developed T cell immunity. Thus, there is a fine balance between the host immune response that controls infection and the pathogen’s ability to evade and manipulate this response.

To better understand the molecular basis for Mtb’s ability to resist host defense mechanisms we characterize Mtb mutants that are susceptible to stresses encountered by the bacterium during persistence within the host. In an infected host, Mtb primarily resides within the phagosomes of macrophages and is able to arrest phagosome maturation. However, after cytokine activation of the macrophage, the phagosome matures along the endosomal-lysosomal pathway. Mtb persists within mature phagosomes, indicating that the bacterium possesses resistance mechanisms against defenses of activated macrophages, such as low pH, nitric oxide and others. We have identified Mtb mutants that are hyper susceptible to such stress conditions. Some of these mutants are also attenuated in the mouse model of TB. The identification and characterization of the molecular mechanisms underlying the loss of stress resistance and loss of virulence of these mutants will help better understand the intracellular environment encountered by Mtb and how the pathogen resists host defense mechanisms.

We are also interested in the metabolic environment Mtb faces within its host. Metabolic adaptation to the host niche is a defining feature of the pathogenicity of Mtb, yet Mtb’s central carbon metabolism remains remain incompletely defined. We are investigating the metabolic pathways Mtb requires to establish and maintain chronic infections.

In collaboration with Dr. Schnappinger’s laboratory (Department of Microbiology, Weill Medical College of Cornell University) we developed controlled expression systems that allow silencing of mycobacterial genes in vitro and in vivo. We apply these systems to create conditional knock-downs of mycobacterial genes that are important for growth and persistence within the host. These conditional knock-downs allow us to investigate if a mycobacterial gene is required at all or only at specific stages of an infection. They also are also used for drug target evaluation and studies of essential mycobacterial genes.

Keywords:
infectious disease, tuberculosis, macrophage, host response, carbon metabolism

Email address:sae2004@med.cornell.edu

Highlights

  1. 1
    Proceedings of the National Academy of Sciences of the United States of America · 2021
    PMID: 34341117PMCID: PMC8364206DOISenior author69 citations
  2. 2
    mBio · 2020
    PMID: 32127458PMCID: PMC7064781DOISenior author44 citations
  3. 3
    Nature communications · 2021
    PMID: 34782606PMCID: PMC8593149DOISenior author31 citations

Publications

148 publications

Active

17 grants
  • MPI
    Determinants of TB Control, Relapse, and Reinfection
    National Institute of Allergy and Infectious Diseases · 2026–2031
  • Co-I
    Microbiology of Treatment Shortening in Tuberculosis
    National Institute of Allergy and Infectious Diseases · 2026–2031
  • PI
    Mechanisms and Consequences of Clinical Pressure on Pathways in Mtb
    National Institute of Allergy and Infectious Diseases · 2020–2031· 2 renewals
  • KP
    TB gene modulation to build shorter drug regimens
    Bill & Melinda Gates Foundation · 2026–2029
    INV-100452
  • MPI
    Understanding resistance and tolerance to nitroimidazoles in Mycobacterium tuberculosis
    National Institute of Allergy and Infectious Diseases · 2025–2029
  • Sub-PI
    Molecular basis of antibiotic resilience in Mycobacterium tuberculosis
    National Institute of Allergy and Infectious Diseases · 2024–2029 · via Harvard University
  • Co-I
    Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium
    National Institute of Allergy and Infectious Diseases · 2024–2029 · via University of California, San Francisco
  • Sub-PI
    Pulmonary TB-CHIM Programme
    Wellcome Trust · 2025–2028 · via Harvard University
    WC-206057-206058
  • MPI
    M. tuberculosis carbon metabolism during infection
    National Institute of Allergy and Infectious Diseases · 2023–2028
  • MPI
    Conditional M. tuberculosis knockdown mutants in mice with human-like pathology
    National Institute of Allergy and Infectious Diseases · 2026–2028
  • MPI
    Tri-Institutional Tuberculosis Research Advancement Center
    National Institute of Allergy and Infectious Diseases · 2022–2027
  • Co-I
    The Transmission Biology of Mycobacterium Tuberculosis
    National Institute of Allergy and Infectious Diseases · 2021–2027Career
  • Co-I
    Gene inactivation and modulation of Mtb targets to build combinations
    Bill & Melinda Gates Foundation · 2023–2026
    BMGF INV-055894
  • Co-I
    Conditional Mtb knockdown mutants for TB drug discovery
    Bill & Melinda Gates Foundation · 2023–2026
    BMGF INV-055896
  • Sub-PI
    Harnessing B Cells For TB Vaccine Development To Improve Therapy Of TB And TB-HIV Coinfection
    National Institute of Allergy and Infectious Diseases · 2021–2026 · via Center for Discovery and Innovation
  • Co-I
    Chemical Genomics of Tuberculosis
    Bill & Melinda Gates Foundation · 2022–2026 · via Broad Institute Inc
    BI 230987-03
  • PI
    Determinants of TB control, relapse and reinfection - Foreign Funding Supplement
    National Institute of Allergy and Infectious Diseases · 2021–2026· 2 renewals
Completed grants (26)
  • Co-I
    Development of a comprehensive RNAseq database of hypomorphs for small molecule target Identification against Mycobacterium tuberculosis
    Bill & Melinda Gates Foundation · 2023–2025 · via Broad Institute Inc
    BI 240369-01
  • KP
    Characterization of a mycobacterial determinant of intrinsic multidrug resistance
    Potts Memorial Foundation · 2023–2025
    PMF 231585-01
  • Co-I
    Determination of the mode of action of the antibiotic pyrazinamide
    National Institute of Allergy and Infectious Diseases · 2022–2025
  • PI
    Turning Mycobacterium tuberculosis appetite for fatty acids against itself
    National Institute of Allergy and Infectious Diseases · 2022–2025
  • KP
    Investigating genetic regulators of Mycobacterium tuberculosis cell division and their role in persistent tuberculosis infection
    National Institute of Allergy and Infectious Diseases · 2022–2024Fellowship
  • KP
    Studying the role of macrophages and gluconeogenesis in the regulation of Mycobacterium tuberculosis persistence in a mouse model of latency
    Potts Memorial Foundation · 2021–2024
    PMF 222011-01
  • PI
    Conditional Expression of Mycobacterial Genes
    National Institute of Allergy and Infectious Diseases · 2018–2024
    5 R01 AI063446=15
  • PI
    Conditionally Replicating Mycobacterium Tuberculosis Vaccines
    National Institute of Allergy and Infectious Diseases · 2018–2024
  • KP
    Ironing out mycobacterial persistence: Iron access and utilization in chronic mycobacterial infection
    National Heart, Lung, and Blood Institute · 2020–2024
  • MPI
    Development of a self inactivating, highly effective TB vaccine
    National Institute of Allergy and Infectious Diseases · 2019–2024 · via University of Pittsburgh
  • PI
    Immunology and Microbial Pathogenesis Research Training Program
    National Institute of Allergy and Infectious Diseases · 2019–2024Training
  • Co-I
    Conditional M. tuberculosis knockdown mutants for TB drug discovery (INV-004761)
    Bill & Melinda Gates Foundation · 2020–2023
    BMGF 210849-01
  • KP
    Defining Mycobacterium tuberculosis as a lung pathobiont
    National Science Foundation · 2020–2023Fellowship
    NSF 1746886
  • Sub-PI
    Chemigenomic Drug Discovery for Tuberculosis
    U.S. Department of Defense · 2017–2022 · via Harvard University
    W81XWH-17-PRMRP-FPA
  • Co-I
    Chemical Genomics of Tuberculosis
    Bill & Melinda Gates Foundation · 2018–2022 · via Broad Institute Inc
    OPP 1207840
  • Co-I
    Vulnerability of M. Tuberculosis to Partial Gene Inactivation
    Bill & Melinda Gates Foundation · 2017–2021
    BMGF INV-009731
  • KP
    Tri-Institutional TB Research Unit: Persistence and Latency
    National Institute of Allergy and Infectious Diseases · 2014–2021· 2 renewals
  • Co-I
    Conditional M. Tuberculosis Knockdown Mutants for TB Drug Development
    Bill & Melinda Gates Foundation · 2017–2020
    BMGF OPP1024065
  • Co-I
    Conditionally Replicating Strains of BCG
    National Cancer Institute · 2018–2019 · via Harvard T. H. Chan School of Public Health
    HHSN2612015000031
  • Co-I
    Decoding the Roles of Critical Genes of Unknown Function in M. tuberculosis
    National Institute of Allergy and Infectious Diseases · 2013–2019 · via Harvard University
  • KP
    Conditional M. Tuberculosis Knockdown Mutants for TB Drug Development
    Bill & Melinda Gates Foundation · 2010–2018
    OPP1024065
  • KP
    Comprehensive Chemigenomic Approach to Tuberculosis (CCAT)
    Bill & Melinda Gates Foundation · 2014–2018 · via Broad Institute Inc
    OPP1084233
  • PI
    Conditional Expression of Mycobacterial Genes
    National Institute of Allergy and Infectious Diseases · 2012–2018
  • PI
    Drug Targets in Mtb Gluconeogenesis
    National Institute of Allergy and Infectious Diseases · 2010–2016
  • PI
    pH Homeostasis in Mycobacterium Tuberculosis
    National Institute of Allergy and Infectious Diseases · 2009–2014
  • PI
    Macrophage Gene Expression: Impact of M. tuberculosis
    NHLBI · 2001–2007 · via NIH RePORTER

Honors & distinctions

3 honors
  • Outstanding Teaching and Mentoring Award · Weill Cornell Medicine · 2020
  • Excellence in Mentoring Award · Weill Cornell Medicine Postdoctoral Association
  • Outstanding Teaching and Mentoring Award · Weill Cornell Graduate School of Medical Sciences

News mentions

Show 3 more mentions
6 PhD students · 9 Postdocs

External relationships

Advisory/Scientific Board Member

Heiser Program for Research in Leprosy & Tuberculosis · TB Alliance